Get the Stockscreener App
12.09
11.12%
1.21
After Hours:
11.50
-0.59
-4.88%
Adlai Nortye Ltd Adr stock is traded at $12.09, with a volume of 863.94K.
It is up +11.12% in the last 24 hours and down -19.40% over the past month.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
See More
Previous Close:
$10.88
Open:
$11.23
24h Volume:
863.94K
Relative Volume:
1.86
Market Cap:
$778.57M
Revenue:
$5.01M
Net Income/Loss:
$-35.62M
P/E Ratio:
-12.02
EPS:
-1.0062
Net Cash Flow:
$-33.55M
1W Performance:
-22.05%
1M Performance:
-19.40%
6M Performance:
-8.75%
1Y Performance:
+628.31%
1-Day Range:
$11.23
$12.46
1-Week Range:
$10.80
$16.73
52-Week Range:
$0.8786
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
12.09 | 778.57M | 5.01M | -35.62M | -33.55M | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-26 | Initiated | Jefferies | Buy |
| Jun-22-26 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-26 | Initiated | Oppenheimer | Outperform |
| Mar-20-26 | Initiated | Leerink Partners | Outperform |
| Feb-13-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
View All
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab - GlobeNewswire Inc.
ADARx Pharmaceuticals, Inc. (ADRX) Stock Price & News - Syfe
Adlai Nortye director Ji Ping sells $83,150 in shares - Investing.com
Adlai Nortye director Ji Ping sells $83,150 in shares By Investing.com - Investing.com Nigeria
Adlai Nortye (NASDAQ: ANL) director lines up ADS sale - Stock Titan
Adlai Nortye (NASDAQ: ANL) readies new offerings as holders plan a large ADS resale - Stock Titan
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Australia
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Canada
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - investing.com
Adlai Nortye (NASDAQ: ANL) Initiates Global Phase I Trial for AN4035 with Phase Ia Data Expected in Late 2027 - Kalkine Media
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035 - TipRanks
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Adlai Nortye stock with buy rating - investing.com
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Canada
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com Canada
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com UK
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com India
Adlai Nortye doses first patient in AN4035 cancer trial - Investing.com
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com UK
Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions - Kalkine Media
Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes - TipRanks
Adlai Nortye (ANL) sets vote on new share authorization - Stock Titan
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares - Stock Titan
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Zacks Investment Research
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportComposite Profile - siam.in
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportComposite Profile - siam.in
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportTechnical Analysis Picks - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com Nigeria
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com Canada
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adlai Nortye Ltd Adr Stock (ANL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ji Ping | Director |
Sep 29 '26 |
Sale |
15.77 |
214 |
3,375 |
131,453 |
| Ji Ping | Director |
Sep 29 '26 |
Proposed Sale |
15.28 |
80,000 |
1,222,400 |
0 |
| Ji Ping | Director |
Sep 22 '26 |
Sale |
16.63 |
5,000 |
83,150 |
131,667 |
| Ye Xiaofeng | CFO |
Aug 26 '26 |
Sale |
14.25 |
5,667 |
80,755 |
147,757 |
| Ye Xiaofeng | CFO |
Aug 24 '26 |
Sale |
13.98 |
6,000 |
83,880 |
153,424 |
| LU YANG | CEO |
May 13 '26 |
Sale |
13.18 |
10 |
132 |
99,990 |
3.36%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):